Provectus Biopharmaceuticals, Inc. financial data

Symbol
PVCT on OTC
Industry
Pharmaceutical Preparations
Location
800 S. Gay Street, Suite 1610, Knoxville, TN
State of incorporation
DE
Fiscal year end
December 31
Former names
PROVECTUS PHARMACEUTICALS INC (to 12/18/2013), PROVECTUS PHARMACEUTICAL INC (to 5/15/2002), ZAMAGE DIGITAL IMAGING INC (to 4/1/2002), SPM GROUP INC (to 11/14/2001)
Latest financial report
10-K - Q4 2024 - Mar 28, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 11.8 % -31.2%
Debt-to-equity -114 % +6.55%
Return On Equity 71.9 % +70.3%
Return On Assets -506 % -167%
Operating Margin -734 % -41.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 420M shares +0.18%
Common Stock, Shares, Outstanding 420M shares +0.18%
Entity Public Float 51.6M USD +13.4%
Common Stock, Value, Issued 420K USD +0.18%
Weighted Average Number of Shares Outstanding, Basic 420M shares +0.07%
Weighted Average Number of Shares Outstanding, Diluted 420M shares +0.07%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 617K USD +10.7%
Research and Development Expense 2M USD +14.3%
General and Administrative Expense 3.15M USD +84.3%
Operating Income (Loss) -4.53M USD -56.2%
Nonoperating Income (Expense) -230K USD -14.6%
Net Income (Loss) Attributable to Parent -4.73M USD -52.6%
Earnings Per Share, Basic -0.01 USD/shares 0%
Earnings Per Share, Diluted -0.01 USD/shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 307K USD +301%
Other Assets, Current 236K USD
Assets, Current 977K USD -28.4%
Property, Plant and Equipment, Net 4.86K USD -59.5%
Operating Lease, Right-of-Use Asset 24.6K USD -65.8%
Assets 1.01M USD -30.5%
Accounts Payable, Current 1.11M USD -34%
Employee-related Liabilities, Current 77.5K USD -96.7%
Liabilities, Current 6.98M USD -22.6%
Operating Lease, Liability, Noncurrent 12.7K USD -79.4%
Liabilities 6.98M USD -22.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -60.7K USD -0.96%
Retained Earnings (Accumulated Deficit) -257M USD -1.87%
Stockholders' Equity Attributable to Parent -5.96M USD +21.5%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -5.97M USD +21.4%
Liabilities and Equity 1.01M USD -30.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.04M USD -67.4%
Net Cash Provided by (Used in) Financing Activities 781K USD +51.5%
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 420M shares +0.18%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -264K USD -139%
Deferred Tax Assets, Valuation Allowance 47M USD -0.7%
Deferred Tax Assets, Gross 47.1M USD -0.76%
Operating Lease, Liability 25.3K USD -65.5%
Depreciation 2.23K USD +0.05%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -4.76M USD -52.3%
Lessee, Operating Lease, Liability, to be Paid 25.7K USD -66.4%
Operating Lease, Liability, Current 25.3K USD -47.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 25.7K USD +0%
Lessee, Operating Lease, Liability, to be Paid, Year One 12.8K USD -74.7%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 370 USD -87.5%
Deferred Tax Assets, Operating Loss Carryforwards 41.5M USD -1.03%
Preferred Stock, Shares Authorized 25M shares 0%
Operating Lease, Payments 11.6K USD +8.36%
Additional Paid in Capital 251M USD +2.61%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%